Active, not recruitingPhase 3NCT05444257
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
Studying Congenital pulmonary airway malformation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Intervention
- VX-121/TEZ/D-IVA(drug)
- Enrollment
- 822 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2022 – 2026
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Banner University of Arizona Medical Center, Tucson, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Miller Children's Hospital / Long Beach Memorial, Long Beach, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Kaiser Permanente, Oakland, California, United States
- University of California Davis Medical Center, Sacramento, California, United States
- University of California San Francisco, Lung Transplant Program, San Francisco, California, United States
- Children's Hospital of Colorado, Aurora, Colorado, United States
- National Jewish Health, Denver, Colorado, United States
- University of Florida, Shands Hospital, Gainesville, Florida, United States
- Joe DiMaggio Cystic Fibrosis & Pulmonary Center, Hollywood, Florida, United States
- University of Miami Miller School of Medicine, Miami, Florida, United States
- Central Florida Pulmonary Group,PA, Orlando, Florida, United States
- Nemours Children's Specialty Care, Pensacola, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05444257 on ClinicalTrials.govOther trials for Congenital pulmonary airway malformation
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07569419Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic FibrosisUniversity of Nottingham
- RECRUITINGNANCT06132048A Usability Validation of the MuCopilot Mobile Application, a Digital Tool for the Unsupervised Objective Assessment of Cystic FibrosisAd scientiam
- ACTIVE NOT RECRUITINGNCT06371261Pathogenicity of Species of the Achromobacter Genus in Patients From Reunion Island With Cystic FibrosisCentre Hospitalier Universitaire de la Réunion
- RECRUITINGNANCT06302985Atomized Inhalation ICG for Treatment of Congenital Lung MalformationsJiexiong Feng
- ACTIVE NOT RECRUITINGNCT07568119Feasibility and Acceptance of SonoHeal for Airway Clearance and Preliminary Comparison With the Standard of CareCognita Labs LLC
- RECRUITINGPHASE1NCT05504837A Study Assessing KB407 for the Treatment of Cystic FibrosisKrystal Biotech, Inc.
- RECRUITINGNANCT05701514The COllaborative Neonatal Network for the First CPAM TrialErasmus Medical Center
- RECRUITINGNCT02270476Longitudinal Observational Study on the Course of Cystic Fibrosis Lung Disease in Patients Following Newborn ScreeningHeidelberg University
See all trials for Congenital pulmonary airway malformation →